Pilot study in humans on the pharmacokinetics and safety of propofol 6% SAZN

Pharmacy World and Science

Volumn 21, Issue 5, 1999, Pages 239-240

  Knibbe, Catherijne A J ^a   Koster, Victorine S ^a   Aarts, Leon P H J ^a   Langemeijer, Han J M ^a   Danhof, Meindert ^b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Anaesthesia; Clinical pharmacology; Emulsion formulation; Fat emulsion; Pharmacokinetics; Propofol

Indexed keywords

LIPOFUNDIN; PROPOFOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SAFETY; FEMALE; HUMAN; SEDATION;

ADULT; ANESTHETICS, INTRAVENOUS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; PILOT PROJECTS; PROPOFOL; TIME FACTORS;

EID: 0032847916     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008701004814     Document Type: Article

References (10)

1. Bryson HM, Fulton BR, Faulds D. Propofol. An update of its use in anaesthesia and conscious sedation. Drugs 1995;50:513-59.
2. Fulton B, Sorkin EM. Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Drugs 1995;50:636-57.
3. Gottardis M, Khünl-Brady KS, Koller W, Sigl G, Hackl JM. Effect of prolonged sedation with propofol on serum triglyceride and cholesterol concentrations. Br J Anaesth 1989;62:393-6.
4. Parke TJ, Stevens JE, Rice ASC, et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ 1992;305:613-6.
5. Knibbe CAJ, Koster VS, Deneer VHM, Stuurman RM, Kuks PFM, Lange R. Determination of propofol in low volume samples by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 1998;706:305-10.
6. Cummings GC, Dixon J, Kay NH, et al. Dose requirements of ICI 35,868 (Propofol, 'Diprivan') in a new formulation for induction of anaesthesia. Anaesthesia 1984;39:1168-71.
7. Dutta S, Matsumoto Y, Ebling WF. Propofol pharmacokinetics and pharmacodynamics assessed from a cremophor EL formulation. J Pharm Sci 1997;86:967-9.
8. Dutta S, Ebling WF. Emulsion formulation reduces propofol dose requirements and enhances safety. Anesthesiology 1997;87:1394-405.
9. Doenicke AW, Roizen MF, Rau J, et al. Pharmacokinetics and pharmacodynamics of propofol in a new solvent. Anesth Analg 1997;85:1399-403.
10. Cox EH, Knibbe CAJ, Koster VS, et al. Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol. Pharm Res 1998;15:442-8.